Aptamer-Drug Conjugate Design for Targeting

Name: Aptamer-PROTAC Conjugates Design
Brand: BOC Sciences

Aptamer-PROTAC conjugates are an emerging targeted protein degradation modality designed to combine the cell-recognition capability of aptamers with the catalytic degradation mechanism of PROTACs. This approach is attracting growing interest because many PROTAC programs still face practical challenges related to selective delivery, intracellular exposure, solubility balance, and target accessibility. By integrating aptamer engineering, degrader design, and conjugation strategy, aptamer-PROTAC constructs can be tailored to improve cell-specific uptake, support controlled intracellular payload release, and expand the utility of targeted protein degradation for difficult biological systems. Leveraging extensive experience in targeted protein degradation, conjugation chemistry, and functional molecule design, BOC Sciences offers end-to-end Aptamer-PROTAC conjugates design services to help clients build rational, research-ready constructs for discovery and translational research.

Request a Consultation Explore Services

What are Aptamer-PROTAC Conjugates?

Aptamer-PROTAC conjugates are chimeric molecular systems in which a targeting aptamer is chemically connected to a PROTAC payload through a rationally designed linker. The aptamer component can be selected to recognize cell-surface receptors, membrane-associated biomarkers, or other disease-relevant binding sites, enabling preferential accumulation and uptake in target cells. Once internalized, the construct is engineered to preserve or release the PROTAC in a form that can engage the protein of interest and recruit an E3 ligase, thereby promoting ubiquitination and proteasome-dependent degradation. Compared with unconjugated degraders, this format offers a promising route to improve cellular selectivity, reduce unwanted distribution, and address delivery bottlenecks in complex discovery programs.

Structure diagram of Aptamer-PROTAC conjugates Fig.1 Aptamer-PROTAC conjugate structural composition schematic (BOC Sciences).

Services

BOC Sciences Aptamer-PROTAC Conjugates Capabilities

Aptamer Selection and Engineering We support the design of targeting aptamers for Aptamer-PROTAC programs based on receptor biology, binding mode, sequence architecture, and downstream conjugation compatibility. Drawing on our experience in aptamer-drug conjugates design, we help optimize affinity, sequence stability, structural integrity, and payload attachment sites to improve targeting precision and construct robustness.
PROTAC Design and Synthesis We provide integrated degrader design services covering target binder selection, warhead positioning, exit vector analysis, and physicochemical optimization. Our team also supports ligand design for E3 ligase selection to build productive degradation systems compatible with aptamer-guided delivery strategies.
Linker Design and Optimization Linker architecture is critical in Aptamer-PROTAC conjugates because it influences folding, steric accessibility, uptake behavior, and payload release. We design cleavable or non-cleavable linker systems with tuned length, flexibility, polarity, and release logic to balance aptamer recognition with degrader performance.
Conjugation Chemistry Development Our scientists develop fit-for-purpose conjugation routes for aptamer-payload assembly, including functional group installation, site-aware coupling strategy selection, and construct purification. We focus on preserving aptamer binding behavior while maintaining the structural features required for productive PROTAC activity.
Uptake and Delivery Optimization Since cellular entry remains a major challenge for many degraders, we offer strategy support for receptor-mediated internalization, endosomal escape considerations, and exposure optimization. Our experience in PROTAC delivery helps clients refine construct properties for more effective intracellular access.
In Vitro Functional Validation We evaluate Aptamer-PROTAC conjugates for binding, internalization, target engagement, degradation activity, and mechanistic performance in relevant cell-based systems. When needed, we can further support mechanistic confirmation using a PROTAC ternary complex assay to clarify degrader behavior during lead optimization.

Looking to Improve Cell-Selective PROTAC Delivery?

We help design Aptamer-PROTAC conjugates with balanced targeting, linker logic, and degradation efficiency for demanding research programs.

Get a Quote

Platforms

Our Technical Platforms & Methods Supporting Aptamer-PROTAC Design

Computational Design We integrate computational tools to support rational Aptamer-PROTAC design, helping clients improve target selection, binding mode analysis, structural compatibility, and construct optimization at the early discovery stage. AI-enabled bioinformatics design Molecular docking analysis Molecular dynamics simulation
Chemical Synthesis Our chemical synthesis platform supports the efficient construction of Aptamer-PROTAC conjugates through precise oligonucleotide preparation, payload assembly, and tailored conjugation chemistry development. Solid-phase synthesis Site-specific conjugation Scaffold modification
Validation and Optimization We perform systematic evaluation and iterative optimization to improve biological performance, linker behavior, and overall construct quality for Aptamer-PROTAC candidates. Cell activity screening DMPK evaluation Linker optimization
Process Development and Production Our process development and production capabilities help translate design concepts into robust and scalable workflows, supporting reproducibility, process understanding, and efficient material preparation. Synthetic route exploration Process safety studies Purification method development

Advantages

Key Advantages of Aptamer-PROTAC Conjugates

Cell-Selective Targeting

Aptamers can be engineered to recognize defined cellular markers, helping direct PROTAC payloads toward selected cell populations and improving experimental precision in heterogeneous biological systems.

Improved Delivery Logic

By coupling a degrader with a targeting nucleic acid ligand, Aptamer-PROTAC constructs offer a practical strategy to address delivery limitations that can reduce the effectiveness of standalone PROTAC molecules.

Modular Design Flexibility

Aptamer sequence, linker architecture, and PROTAC payload can each be independently tuned, allowing rapid design iteration around target biology, uptake behavior, and intracellular degradation requirements.

Access to Difficult Targets

This modality may broaden the application space of targeted protein degradation by combining receptor-aware delivery with catalytic protein knockdown for challenging research targets.

Workflow

Our Aptamer-PROTAC Conjugates Development Workflow

01

Project Consultation & Design Goal Definition

We review target biology, intended cell population, degradation objective, and key technical constraints to define a practical design route for your Aptamer-PROTAC construct.

02

Aptamer Strategy Selection

Our team evaluates aptamer sequence format, target-binding rationale, modification strategy, and conjugation position to support specificity and functional compatibility.

03

PROTAC Payload Design

We design the degrader module around target binder selection, E3 ligase recruitment strategy, exit vector placement, and physicochemical balance.

04

Linker Architecture Optimization

Linker composition, length, flexibility, and release behavior are optimized to support aptamer recognition, internalization, and downstream degrader function.

05

Conjugation Route Development

We establish the assembly method, confirm construct integrity, and optimize purification to obtain research-grade Aptamer-PROTAC conjugates suitable for functional evaluation.

06

Cellular Uptake and Mechanistic Assessment

Internalization behavior, intracellular trafficking, and target engagement are examined to verify whether the design logic translates into effective cellular exposure.

07

Degradation Performance Evaluation

We assess target protein reduction, selectivity trends, and supporting mechanistic readouts in relevant cell-based assays to guide further construct refinement.

08

Data Reporting & Iterative Optimization

Clients receive organized technical reports and design recommendations to support next-round optimization, platform expansion, or broader discovery planning.

Start Your Aptamer-PROTAC Conjugates Project Today

Engage with BOC Sciences to build a customized Aptamer-PROTAC design strategy aligned with your target biology and discovery goals.

Talk to Experts

Why Choose Us

BOC Sciences Aptamer-PROTAC Service Advantages

Cross-Disciplinary Design Expertise

We combine experience in aptamer engineering, targeted protein degradation, linker chemistry, and conjugated molecule development to address the multi-parameter complexity of this modality.

Integrated End-to-End Workflow

From aptamer strategy and PROTAC payload design through conjugation development and in vitro validation, we provide a connected workflow that reduces fragmentation across project stages.

Customization for Target Biology

Each construct can be tailored around receptor expression, uptake pathway, degrader mechanism, and downstream assay priorities rather than relying on one-size-fits-all design templates.

Design Focus on Real Delivery Barriers

We address practical challenges such as aptamer stability, linker behavior, internalization efficiency, and intracellular degrader release that frequently determine project success.

Mechanism-Oriented Evaluation Support

Our validation strategies go beyond simple binding checks and are designed to help clarify uptake, degradation, and optimization direction during lead refinement.

Research-Ready Technical Communication

We provide clear project reporting and scientific discussion that help discovery teams make faster decisions on construct prioritization and next-step design.

Applications

Applications of Aptamer-PROTAC Conjugates

Cell-Targeted Protein Degradation Research

Aptamer-PROTAC conjugates can be used to explore whether receptor-guided delivery improves degrader action in defined cell populations and disease-relevant models.

Delivery Optimization for Difficult Degrader Programs

This format is useful when conventional PROTAC molecules show promising biochemical activity but insufficient selectivity, uptake, or intracellular exposure in cellular systems.

Receptor-Driven Oncology Research

Aptamer-guided degraders can support studies that require preferential delivery to tumor-associated or disease-enriched cell populations while preserving degrader functionality.

Target Validation for Challenging Proteins

By pairing selective targeting ligands with catalytic degradation, this modality can support target validation strategies for proteins that are difficult to modulate using conventional approaches.

Mechanistic Studies of Uptake and Degradation

These constructs are useful tools for dissecting the relationship among receptor binding, cellular trafficking, linker release, and downstream degradation activity.

Next-Generation Oligonucleotide-Conjugated Degraders

Aptamer-PROTAC systems can also inform broader research directions in oligonucleotide-based PROTACs development and related targeted degradation platforms.

Case Study

Client Success Stories: Aptamer-PROTAC Conjugates

Project Background

A biotechnology company had developed a BRD4-targeting PROTAC with promising activity, but the molecule showed limited selectivity and inconsistent intracellular exposure in nucleolin-positive cancer models. To improve targeted delivery, the client initiated a nucleolin-targeted Aptamer-PROTAC program with BOC Sciences.

Technical Challenges

Initial testing showed that direct payload attachment weakened nucleolin binding, suggesting disruption of aptamer folding. In addition, the first linker design supported construct formation but gave poor intracellular release and only modest BRD4 degradation.

BOC Sciences Solutions

Aptamer Reformatting: We compared 5′- and 3′-end conjugation and found that one terminus was important for maintaining the active binding conformation. The conjugation site was moved to the opposite end, and a short spacer was introduced to reduce steric interference.
Linker Screening: Several linker variants were evaluated for length, flexibility, and cleavage behavior. A medium-length cleavable linker provided the best balance of aptamer accessibility, construct stability, and intracellular release.
Payload Adjustment: The BRD4 PROTAC attachment vector was redesigned to better preserve degradation activity after conjugation and improve compatibility with the aptamer-guided format.

Project Outcomes

BOC Sciences delivered optimized Aptamer-PROTAC candidates with improved construct integrity and receptor-mediated uptake. The lead conjugate showed stronger internalization in nucleolin-positive cells and improved BRD4 degradation compared with the parent PROTAC in the same in vitro system.

Project Background

A biopharmaceutical client was evaluating a STAT3-targeting PROTAC for EGFR-enriched solid tumor models, but the standalone degrader showed weak cellular entry and inconsistent activity across receptor-positive and receptor-low cells. To improve selective delivery, the client asked BOC Sciences to develop an EGFR-targeted Aptamer-PROTAC conjugate.

Technical Challenges

The client's first-generation construct had three clear problems: the modified EGFR aptamer lost part of its binding activity after payload installation, the coupling route produced several closely related by-products that complicated purification, and the initial conjugate entered cells but did not translate that uptake into efficient STAT3 degradation.

BOC Sciences Solutions

Modified Aptamer Re-Evaluation: We rebuilt several EGFR aptamer variants with different terminal modification patterns and compared binding after reactive handle installation. A 3′-amino-modified format with a short PEG spacer retained receptor binding better than the corresponding 5′-modified design and was selected for downstream assembly.
Assembly Route Redesign: The original one-pot coupling strategy generated multiple side products with similar analytical profiles. We replaced it with a stepwise route separating aptamer functionalization, payload activation, and final coupling, which improved purification efficiency and construct uniformity.
Linker and Payload Presentation Optimization: Because the first screened conjugate showed acceptable uptake but weak degradation, we adjusted spacer length and linker polarity in follow-up constructs. The refined design improved intracellular payload presentation and produced a clearer degradation response in EGFR-high cells.

Project Outcomes

BOC Sciences delivered a more stable and better-defined EGFR-targeted Aptamer-PROTAC construct with improved receptor-associated uptake and stronger STAT3 degradation in EGFR-high cell models than the client's initial design. The comparison across redesigned aptamer, conjugation route, and linker variants also gave the client a practical optimization framework for subsequent candidate refinement.

Frequently Asked Questions (FAQ)

Frequently Asked Questions

Still have questions?

Contact Us

What should be evaluated first in Aptamer-PROTAC design?

For drug development teams, the starting point is usually not drawing the chemical structure first, but confirming three prerequisites: whether the aptamer can stably recognize the target and promote cellular uptake, whether the selected PROTAC warhead already has a validated degradation basis, and whether both parts can retain their functions after conjugation. In real projects, the key priorities are usually target and cell-model fit, modifiable binding positions, intracellular release pathway, and conformational changes after conjugation. BOC Sciences can support this stage through candidate sequence assessment, conjugation site design, and parallel synthesis of multiple constructs to help narrow the design space earlier.

How does the linker affect degradation performance?

The linker often determines whether an Aptamer-PROTAC can merely be conjugated or can truly function as intended. Its length, flexibility, hydrophilicity, attachment position, and cleavable or non-cleavable nature can all influence intracellular release after uptake, ternary complex formation, and overall degradation efficiency. In Aptamer-PROTAC systems, this issue is even more complex because the linker must also balance nucleic acid exposure with the productive conformation of the PROTAC moiety. In development practice, teams usually compare a matrix of short, medium, and long linkers, as well as flexible, semi-rigid, cleavable, and non-cleavable options, rather than relying on a single linker design.

How can the right aptamer be selected?

The most suitable aptamer is not simply the one with the highest affinity. From a drug development perspective, teams should focus on four points: whether it can specifically recognize a defined cell-surface target, whether it can trigger efficient internalization, whether it retains binding activity after chemical modification and conjugation, and whether it shows sufficient selectivity in the intended system. In many cases, project progress is limited not because the PROTAC warhead is ineffective, but because the aptamer fails to deliver the conjugate into the right cells. BOC Sciences can support aptamer modification strategies, conjugation compatibility studies, different attachment-site construction, and early in vitro evaluation workflows to help move a project from binding feasibility to functional degradation.

What are the advantages of Aptamer-PROTAC conjugates?

Compared with using aptamers alone or conventional PROTACs alone, Aptamer-PROTAC conjugates combine targeted recognition with induced protein degradation in one molecular design. The aptamer serves as a recognition and delivery module that can improve enrichment toward specific cells or surface markers, while the PROTAC module recruits an E3 ligase and drives degradation of the protein of interest. This strategy offers greater flexibility in molecular design and gives research teams more room to optimize specificity, intracellular delivery, release behavior, and degradation efficiency in an integrated way.

What is the hardest part of optimizing Aptamer-PROTAC conjugates?

In practice, the hardest part is usually not a single parameter but the coupling of multiple variables. Aptamer modification may reduce binding activity, PROTAC conjugation may alter membrane accessibility and molecular conformation, and the linker may simultaneously affect release, stability, and the degradation window. As a result, a common challenge is that a construct may show promising binding in vitro but insufficient degradation performance in cells. The most effective approach is usually parallel optimization rather than one-point adjustment, including site substitution, linker redesign, warhead switching, and structure-activity relationship validation. For teams seeking external support, BOC Sciences can provide integrated assistance from custom synthesis and conjugation development to early-stage screening material preparation, helping reduce communication burden and repeated trial-and-error during early development.

Testimonials

Client Feedback on Aptamer-PROTAC Conjugates Design

Strong Design Logic

"What impressed us most was the team's ability to connect aptamer engineering with degrader mechanism instead of treating them as separate workstreams. The design recommendations were practical and scientifically well structured."

— Dr. Carter, Senior Scientist at a US Biotech Company

Useful Optimization Support

"BOC Sciences helped us identify where our construct was underperforming and proposed a more effective linker and payload presentation strategy. The technical communication was clear and highly actionable."

— Mr. Bennett, Project Leader at a European Drug Discovery Team

Integrated Validation Perspective

"Their workflow combined design, conjugation, and in vitro assessment in a way that helped us make faster decisions on candidate prioritization for our Aptamer-PROTAC program."

— Dr. Morgan, Principal Investigator at an Oncology Research Program

Responsive Scientific Collaboration

"The team understood the delivery problem behind our degrader project and translated that into a coherent aptamer-guided design strategy. It felt like working with scientists who really know the targeted degradation field."

— Dr. Taylor, Discovery Manager at a UK-Based Biopharma Company